Product Name: Clemastine fumarate
Synonyms: "(2R)-2-[2-[(1R)-1-(4-CHLOROPHENYLETHOXY)]ETHYL]-1-METHYL-2-PYRROLIDINE FUMARATE
CLEMASTINE FUMARATE
CLEMASTINE FUMARATE SALT
(+)-2-(2-((p-chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methylpyrro
(+)-2-(2-((p-chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methylpyrroli
(+)-lfumarate(1:1)
1-methyl-2-(2-(methyl-p-chlorodiphenylmethyloxy)ethyl)pyrrolidine
2-(2-(1-(4-chlorophenyl)-1-phenylethoxy)ethyl)-1-methylpyrrolidine
agasten
aloginan
alphamin
anhistan
clemanil
clemastinehydrogenfumarate
fuluminol
hs592
inbestan
kinotomin
lacretin
lecasol"
CAS: 14976-57-9
MF: C25H30ClNO5
MW: 459.96
EINECS: 239-055-2
Purity ≥99%
Boiling point: 116 °C / 24mmHg
Melting Point 61 °C
Flash point: 211ºC
Density 1.097 g/cm3
Appearance White solid
Storage Store at RT
Solubility : >20 mg/ml in DMSO
Product Categories: Intermediates & Fine Chemicals,Pharmaceuticals
Usage Clemastine Fumarate is a selective histamine H1 receptor antagonist with IC50 of 3 nM.Target: Histamine H1 ReceptorClemastine Fumarate inhibits histamine induced rise in [Ca2+]i in HL-60 cells with an IC50 of 3 nM as compared with that of chlorpheniramine or diphenhydramine with IC50 values of 20 nM and 100 nM, respectively [1]. Clemastine showed a first-pass reduction in the extent of absorption, with oral bioavailability calculated as 39.2 +/- 12.4%. Extravascular distribution of drug was suggested by the high volume of distribution (799 +/- 315 L) and low Cmax (0.577 +/- 0.252 ng/mL/mg) observed at 4.77 +/- 2.26 hours after administration, and by the biphasic decline in plasma concentration. The terminal elimination half-life (t1/2) of clemastine was 21.3 +/- 11.6 hours. Steady-state concentrations of clemastine were consistent with linear pharmacokinetic processes, and clearance was unaffected by age in the range studied, or by race